Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity
NAR Cancer · 11.03.2023 · 5 (2)
DOI: 10.1093/narcan/zcad016 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 19.04.2023. Verfasst von Grace A McCarthy und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Oregon Health & Science University, Portland, OR 97239, USA. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health, Oregon Health & Science University.
Abstract (Originalsprache)
Stromal cells promote extensive fibrosis in pancreatic ductal adenocarcinoma (PDAC), which is associated with poor prognosis and therapeutic resistance. We report here for the first time that loss of the RNA-binding protein human antigen R (HuR, ELAVL1) in PDAC cells leads to reprogramming of the tumor microenvironment. In multiple in vivo models, CRISPR deletion of ELAVL1 in PDAC cells resulted in a decrease of collagen deposition, accompanied by a decrease of stromal markers (i.e. podoplanin, α-smooth muscle actin, desmin). RNA-sequencing data showed that HuR plays a role in cell–cell communication. Accordingly, cytokine arrays identified that HuR regulates the secretion of signaling molecules involved in stromal activation and extracellular matrix organization [i.e. platelet-derived growth factor AA (PDGFAA) and pentraxin 3]. Ribonucleoprotein immunoprecipitation analysis and transcription inhibition studies validated PDGFA mRNA as a novel HuR target. These data suggest that tumor-intrinsic HuR supports extrinsic activation of the stroma to produce collagen and desmoplasia through regulating signaling molecules (e.g. PDGFAA). HuR-deficient PDAC in vivo tumors with an altered tumor microenvironment are more sensitive to the standard of care gemcitabine, as compared to HuR-proficient tumors. Taken together, we identified a novel role of tumor-intrinsic HuR in its ability to modify the surrounding tumor microenvironment and regulate PDGFAA.
Autor:innen und Institutionen
- Department of Surgery, Oregon Health & Science University, Portland, OR 97239, USA.
- Brenden-Colson Center for Pancreatic Care, Oregon Health & Science University, Portland, OR 97201, USA.
- Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97201, USA.
- The Jefferson Pancreas, Biliary and Related Cancer Center, Department of Surgery, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- Department of Diagnostic Radiology, Oregon Health & Science University, Portland, OR 97239, USA.
- Advanced Imaging Research Center, Oregon Health & Science University, Portland, OR 97239, USA.
ORCID-Profile: Grace A McCarthy, Jennifer M Finan, Aditi Jain
Förderung
- NCI NIH HHS
- National Institutes of Health
- Oregon Health & Science University
- OHSU Knight Cancer Institute
- Code Biotherapeutics
- Hirshberg Foundation for Pancreatic Cancer Research
- Sarah Parvin Foundation
Zitieren
APA
McCarthy, G. A., Di Niro, R., Finan, J. M., Jain, A., Guo, Y., Wyatt, C. R., Guimaraes, A. R., Waugh, T. A., Keith, D., Morgan, T. K., Sears, R. C., & Brody, J. R. (2023). Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. NAR Cancer, 5(2). https://doi.org/10.1093/narcan/zcad016
Vancouver
McCarthy GA, Di Niro R, Finan JM, Jain A, Guo Y, Wyatt CR, et al. Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity. NAR Cancer. 2023;5(2). doi:10.1093/narcan/zcad016
BibTeX
@article{McCarthy2023,
author = {McCarthy, Grace A and Di Niro, Roberto and Finan, Jennifer M and Jain, Aditi and Guo, Yifei and Wyatt, Cory R and Guimaraes, Alexander R and Waugh, Trent A and Keith, Dove and Morgan, Terry K and Sears, Rosalie C and Brody, Jonathan R},
title = {Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity},
journal = {NAR Cancer},
year = {2023},
volume = {5},
number = {2},
doi = {10.1093/narcan/zcad016}
}
EUVIMED